Thomas Jefferson University

Running trials

• Not yet recruiting

  Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis

  NCT07674745· Phase 2· Source

• Recruiting

  A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

  NCT07623161· Phase 3· Source

• Not yet recruiting

  H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)

  NCT07484139· Phase 2· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Source

• Recruiting

  PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis

  NCT07232069· Phase 3· Source

• Recruiting

  A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications

  NCT07330258· Source

• Recruiting

  Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

  NCT07563881· Phase 3· Source

• Recruiting

  Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07562152· Phase 3· Source

• Recruiting

  A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions

  NCT07422480· Phase 3· Source

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Source

• Recruiting

  Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

  NCT07493512· Phase 1· Source

• Recruiting

  A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

  NCT07475806· Phase 2· Source

• Recruiting

  COPD Exacerbation Follow Up

  NCT07118306· Source

• Enrolling by invitation

  Ketone and Hawthorn Extract Supplementation in Congestive Heart Failure

  NCT07166965· Source

• Active, not recruiting

  A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

  NCT07076121· Phase 2/3· Source

• Recruiting

  A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

  NCT07027514· Phase 1· Source

• Recruiting

  PopSci CHW4CervixHealth

  NCT07336134· Source

• Recruiting

  Virtue® SAB in the Treatment of Coronary ISR Trial

  NCT07045194· Source

• Recruiting

  Tebentafusp-tebn With LDT in Metastatic UM

  NCT06626516· Phase 1/2· Source

• Recruiting

  Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

  NCT07140900· Phase 1· Source

• Recruiting

  CGM Adherence Compared to Finger-stick Glucose Monitoring in Pregnancies With Type 2 Pregestational Diabetes

  NCT07184775· Source

• Recruiting

  AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

  NCT07094113· Phase 1· Source

• Enrolling by invitation

  SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures

  NCT07141329· Phase 2· Source

• Recruiting

  Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

  NCT06911632· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Source

• Recruiting

  A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

  NCT06963827· Phase 3· Source

• Recruiting

  Daily Aspirin vs Split Dosing in High-risk Pregnancies (DASH)

  NCT06826859· Phase 1/2· Source

• Recruiting

  A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

  NCT06943872· Phase 3· Source

• Recruiting

  A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  NCT06852222· Phase 3· Source

• Recruiting

  A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT06533644· Phase 2· Source

• Active, not recruiting

  A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  NCT06624085· Phase 1· Source

• Active, not recruiting

  Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis

  NCT06704269· Phase 1/2· Source

• Recruiting

  An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

  NCT06951217· Phase 2· Source

• Recruiting

  Leveraging Lung Cancer Screening to Optimize Screening Outcomes and COPD Management: COPD in LCS Registry

  NCT06974981· Source

• Recruiting

  RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

  NCT06798896· Phase 2· Source

• Recruiting

  A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

  NCT06581406· Phase 2/3· Source

• Recruiting

  A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

  NCT06750094· Phase 3· Source

• Recruiting

  Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

  NCT06613100· Phase 1· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

  NCT06655155· Phase 2· Source

• Recruiting

  A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

  NCT06662786· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

  NCT06625060· Phase 2· Source

• Active, not recruiting

  Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer

  NCT06555796· Phase 1· Source

• Active, not recruiting

  Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

  NCT06564142· Phase 3· Source

• Recruiting

  Reducing Urban Cervical Cancer Disparities

  NCT06416150· Source

• Enrolling by invitation

  Long-term Safety and Tolerability of BHV-7000

  NCT06443463· Phase 2· Source

• Recruiting

  VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

  NCT06264180· Phase 3· Source

• Active, not recruiting

  A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

  NCT06388733· Phase 3· Source

• Recruiting

  IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

  NCT06112314· Phase 3· Source

• Active, not recruiting

  A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

  NCT06329401· Phase 2· Source

• Active, not recruiting

  A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

  NCT06132893· Phase 2/3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Epilepsy5 recruiting
• Prostate cancer5 recruiting
• Lung cancer4 recruiting
• Melanoma4 recruiting
• Bladder cancer3 recruiting
• Childhood cancers3 recruiting
• Colorectal cancer3 recruiting
• High blood pressure3 recruiting
• Idiopathic pulmonary fibrosis3 recruiting
• Type 2 diabetes3 recruiting
• Cervical cancer2 recruiting
• COPD2 recruiting
• Coronary artery disease2 recruiting
• Heart failure2 recruiting
• Pancreatic cancer2 recruiting
• Parkinson disease2 recruiting
• Stroke2 recruiting
• Thyroid cancer2 recruiting
• Acute myeloid leukemia1 recruiting
• ALS (motor neurone disease)1 recruiting
• Alzheimer disease1 recruiting
• Atrial fibrillation1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Endometrial cancer1 recruiting
• Follicular lymphoma1 recruiting
• Head and neck cancer1 recruiting
• HIV1 recruiting
• IgA nephropathy1 recruiting
• Liver and biliary tract cancer1 recruiting
• Multiple sclerosis1 recruiting
• Myasthenia gravis1 recruiting
• Myelodysplastic syndromes1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Obesity1 recruiting
• Ovarian cancer1 recruiting
• Primary biliary cholangitis1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Type 1 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Withdrawn

  Prevention of Coronary Microvascular Dysfunction Post-PCI by Intracoronary Nicardipine

  NCT03184155· Early phase 1· Source

• Completed

  Sanctuary Farm Prescription in Adolescents

  NCT07218588· Source

• Terminated

  VIZ ACCESS HCM - Multi-Site Registry

  NCT07103057· Source

• Completed

  Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy

  NCT06377930· Phase 2· Source

• Recruiting

  Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

  NCT06252649· Phase 3· Source

• Completed

  Testing Design Thinking Methodology to Engage Hispanic and Latino Families of Autistic Children in Research.

  NCT06111092· Source

• Completed

  A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

  NCT06221969· Phase 3· Source

• Terminated

  Study of IK-595 in RAS- or RAF-altered Advanced Tumors

  NCT06270082· Phase 1· Source

• Completed

  A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010

  NCT05867121· Phase 1· Source

• Completed

  Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)

  NCT06060665· Phase 3· Source

• Completed

  Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

  NCT05819359· Phase 2· Source

• Completed

  A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

  NCT05708950· Phase 1/2· Source

• Terminated

  A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL

  NCT05515406· Phase 1· Source

• Withdrawn

  EpiCare@Home Validation Study for Focal Onset Seizures

  NCT05738226· Source

• Completed

  A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

  NCT05559580· Phase 2· Source

• Completed

  A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

  NCT05614063· Phase 3· Source

• Completed

  A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's Participants

  NCT05603312· Phase 1/2· Source

• Withdrawn

  ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures

  NCT05481905· Phase 2· Source

• Completed

  A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)

  NCT05514535· Phase 3· Source

• Completed

  THUNDER: Acute Ischemic Stroke Study With the Penumbra System® Including Thunderbolt™ Aspiration Tubing

  NCT05437055· Source

• Completed

  RNS System NAUTILUS Study

  NCT05147571· Source

• Completed

  Telehealth-enabled Integrated Palliative Care for People With Dementia

  NCT05524181· Source

• Terminated

  A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

  NCT05269355· Phase 2/3· Source

• Completed

  STEM-Parkinson's Disease

  NCT04797611· Source

• Completed

  Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

  NCT05119855· Phase 3· Source

• Completed

  A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment

  NCT05241834· Phase 1· Source

• Completed

  Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

  NCT05103358· Phase 2· Source

• Completed

  Evaluation of Barriers to Cancer Care Delivery and Outcomes for Women of Color With Metastatic Breast Cancer

  NCT06206239· Source

• Terminated

  A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome

  NCT05163314· Phase 3· Source

• Completed

  A Randomized, Controlled Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System (SUMMIT MAX)

  NCT05018650· Source

• Completed

  A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome

  NCT04938427· Phase 3· Source

• Completed

  A Study of SEA-CD40 Given With Other Drugs in Cancers

  NCT04993677· Phase 2· Source

• Completed

  realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL

  NCT04981795· Source

• Completed

  Determination and Validation of a Multi-analyte Assay for Lung Cancer Screening

  NCT04968548· Source

• Terminated

  Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

  NCT04935229· Phase 1· Source

• Completed

  National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer

  NCT04145141· Source

• Completed

  Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy

  NCT04693715· Phase 2· Source

• Terminated

  CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma

  NCT04698187· Phase 2· Source

• Terminated

  CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma

  NCT04695977· Phase 2/3· Source

• Completed

  Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer

  NCT04719273· Phase 2· Source

• Terminated

  A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors

  NCT04442126· Phase 1/2· Source

• Completed

  Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian

  NCT04374630· Phase 2· Source

• Completed

  Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

  NCT04321031· Phase 2· Source

• Completed

  Prevention of Colorectal Cancer Through Multiomics Blood Testing

  NCT04369053· Source

• Terminated

  NOLA (NeuWave Observational Liver Ablation) Registry

  NCT04107766· Source

• Completed

  A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation

  NCT04102098· Phase 3· Source

• Completed

  Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

  NCT03836209· Phase 2· Source

• Completed

  A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations

  NCT04083976· Phase 2· Source

• Completed

  Trial of Parkinson's And Zoledronic Acid

  NCT03924414· Phase 4· Source

• Completed

  Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer

  NCT03941093· Phase 3· Source

Trial sites

• Thomas Jefferson University1 trial
• Duplicate_Thomas Jefferson University /ID# 1680031 trial
• Thomas Jefferson University189 trials
• Thomas Jefferson University, Dept of Radiology1 trial
• Thomas Jefferson University - Family and Community Medicine (Site 0006)1 trial
• Thomas Jefferson University, Investigational Drug Service1 trial
• Thomas Jefferson University - Medical Oncology3 trials
• Thomas Jefferson University_Philadelphia1 trial
• Thomas Jefferson University (Site 1579)1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Prostate cancer68 works · 16 trials
• Melanoma59 works · 14 trials
• Epilepsy39 works · 16 trials
• Migraine36 works · 1 trials
• Glaucoma33 works · 0 trials
• Sickle cell disease24 works · 1 trials
• Head and neck cancer13 works · 7 trials
• ALS (motor neurone disease)12 works · 2 trials
• Myasthenia gravis7 works · 2 trials
• Neuromyelitis optica (NMOSD)5 works · 0 trials
• High blood pressure4 works · 5 trials